Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19749740rdf:typepubmed:Citationlld:pubmed
pubmed-article:19749740lifeskim:mentionsumls-concept:C0206694lld:lifeskim
pubmed-article:19749740lifeskim:mentionsumls-concept:C0332466lld:lifeskim
pubmed-article:19749740lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:19749740lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:19749740lifeskim:mentionsumls-concept:C1519595lld:lifeskim
pubmed-article:19749740pubmed:issue12lld:pubmed
pubmed-article:19749740pubmed:dateCreated2009-11-30lld:pubmed
pubmed-article:19749740pubmed:abstractTextMucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. We and others showed that CRTC1-MAML2 gene fusion was associated with favorable clinicopathological tumor features. Recently, a novel gene fusion, CRTC3-MAML2, was reported as a rare gene alteration in a case of mucoepidermoid carcinoma. However, its frequency and clinicopathological significance remains unclear. In all, 101 cases of mucoepidermoid carcinoma and 89 cases of non-mucoepidermoid carcinoma of the salivary gland were analyzed, and RNA was extracted from formalin-fixed, paraffin-embedded specimens. In the CRTC family, there have been three genes, CRTC1, CRTC2, and CRTC3. We developed reverse transcription-polymerase chain reaction (RT-PCR) assays for CRTC1-MAML2, CRTC2-MAML2, and CRTC3-MAML2 fusions. Clinicopathological data of the patients were obtained from their clinical records. Of 101 cases of mucoepidermoid carcinoma, 34 (34%) and 6 (6%) were positive for CRTC1-MAML2 and CRTC3-MAML2 fusion transcripts. However, in the 89 cases of non-mucoepidermoid carcinoma, neither transcript was noted. In the former cases, CRTC1-MAML2 and CRTC3-MAML2 fusions were mutually exclusive. The other fusion, CRTC2-MAML2, was not detected. We confirmed that the clinicopathological features of CRTC1-MAML2-positive mucoepidermoid carcinomas indicated an indolent course. CRTC3-MAML2-positive mucoepidermoid carcinomas also had clinicopathologically favorable features; all cases showed a less advanced clinical stage, negative nodal metastasis, no high-grade tumor histology, and no recurrence or tumor-related death after surgical resection of the tumor. It is interesting to note that patients with CRTC3-MAML2-positive tumors (mean 36 years of age) were significantly younger that those with the CRTC1-MAML2 fusion (55 years) and those with fusion-negative tumors (58 years). In conclusion, CRTC3-MAML2 fusion, which is mutually exclusive with CRTC1-MAML2 fusion and specific to mucoepidermoid carcinoma, may be detected more frequently than previously expected. Mucoepidermoid carcinomas possessing CRTC3-MAML2 fusion may be associated with favorable clinicopathological features and patients may be younger than those with CRTC1-MAML2 fusion or those with no detectable gene fusion.lld:pubmed
pubmed-article:19749740pubmed:languageenglld:pubmed
pubmed-article:19749740pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:citationSubsetIMlld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19749740pubmed:statusMEDLINElld:pubmed
pubmed-article:19749740pubmed:monthDeclld:pubmed
pubmed-article:19749740pubmed:issn1530-0285lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:InagakiHirosh...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:OkabeMitsukun...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:HasegawaYasuh...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:NagatsukaHito...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:ShimozatoKazu...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:IjichiKeiKlld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:SakumaHidenor...lld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:MiyabeSatoruSlld:pubmed
pubmed-article:19749740pubmed:authorpubmed-author:NakayamaTakah...lld:pubmed
pubmed-article:19749740pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19749740pubmed:volume22lld:pubmed
pubmed-article:19749740pubmed:ownerNLMlld:pubmed
pubmed-article:19749740pubmed:authorsCompleteYlld:pubmed
pubmed-article:19749740pubmed:pagination1575-81lld:pubmed
pubmed-article:19749740pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:meshHeadingpubmed-meshheading:19749740...lld:pubmed
pubmed-article:19749740pubmed:year2009lld:pubmed
pubmed-article:19749740pubmed:articleTitleClinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma.lld:pubmed
pubmed-article:19749740pubmed:affiliationDepartment of Pathology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.lld:pubmed
pubmed-article:19749740pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:64784entrezgene:pubmedpubmed-article:19749740lld:entrezgene
entrez-gene:84441entrezgene:pubmedpubmed-article:19749740lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19749740lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19749740lld:entrezgene